Satellos Bioscience Inc
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy di… Read more
Satellos Bioscience Inc (MSCLF) - Net Assets
Latest net assets as of September 2025: $34.00 Million USD
Based on the latest financial reports, Satellos Bioscience Inc (MSCLF) has net assets worth $34.00 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($37.50 Million) and total liabilities ($3.50 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $34.00 Million |
| % of Total Assets | 90.66% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 388.36 |
Satellos Bioscience Inc - Net Assets Trend (2020–2024)
This chart illustrates how Satellos Bioscience Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Satellos Bioscience Inc (2020–2024)
The table below shows the annual net assets of Satellos Bioscience Inc from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $47.28 Million | +54.22% |
| 2023-12-31 | $30.66 Million | +810.20% |
| 2022-12-31 | $3.37 Million | -67.86% |
| 2021-12-31 | $10.48 Million | +5801.88% |
| 2020-12-31 | $-183.84K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Satellos Bioscience Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4789103908.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $99.96 Million | 211.40% |
| Total Equity | $47.28 Million | 100.00% |
Satellos Bioscience Inc Competitors by Market Cap
The table below lists competitors of Satellos Bioscience Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AAPICO Hitech Public Company Limited
BK:AH
|
$75.69 Million |
|
CPI CARD GROUP DL-001
F:CPB1
|
$75.69 Million |
|
Koryx Copper Inc.
OTCQB:KRYXF
|
$75.70 Million |
|
SOUTH MANGAN.INV. HD-05
F:00D0
|
$75.72 Million |
|
Pacific Century Regional Developments Limited
F:PFQ
|
$75.65 Million |
|
ATW Technology Inc
TWO:8097
|
$75.62 Million |
|
Falcon Oil & Gas Ltd.
PINK:FOLGF
|
$75.61 Million |
|
Xingguang Agricultural Mach
SHG:603789
|
$75.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Satellos Bioscience Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 30,660,335 to 47,284,332, a change of 16,623,997 (54.2%).
- Net loss of 19,578,592 reduced equity.
- New share issuances of 29,823,229 increased equity.
- Other factors increased equity by 6,379,360.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-19.58 Million | -41.41% |
| Share Issuances | $29.82 Million | +63.07% |
| Other Changes | $6.38 Million | +13.49% |
| Total Change | $- | 54.22% |
Book Value vs Market Value Analysis
This analysis compares Satellos Bioscience Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.69x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-0.01 | $0.48 | x |
| 2021-12-31 | $0.32 | $0.48 | x |
| 2022-12-31 | $0.08 | $0.48 | x |
| 2023-12-31 | $0.27 | $0.48 | x |
| 2024-12-31 | $0.29 | $0.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Satellos Bioscience Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -41.41%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.08x
- Recent ROE (-41.41%) is above the historical average (-112.90%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.56 Million |
| 2021 | -147.92% | 0.00% | 0.00x | 1.20x | $-16.55 Million |
| 2022 | -336.12% | 0.00% | 0.00x | 1.84x | $-11.66 Million |
| 2023 | -39.06% | 0.00% | 0.00x | 1.09x | $-15.04 Million |
| 2024 | -41.41% | 0.00% | 0.00x | 1.08x | $-24.31 Million |
Industry Comparison
This section compares Satellos Bioscience Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Satellos Bioscience Inc (MSCLF) | $34.00 Million | 0.00% | 0.10x | $75.67 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |